Arbitrators cleared the way for the long-delayed $53 billion acquisition after Exxon tried to pre-empt the deal. 3M raised its full-year earnings outlook after beating expectations in the second ...

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

The analyst further reasoned that the high ocular toxicity rates, including keratopathy and visual acuity changes, are ...

The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U.S.

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL patients who are not eligible for autologous stem cell transplant, Roche ...

By Sanchayaita Roy and Twesha Dikshit (Reuters) -European shares were unchanged on Friday, as losses in heavyweight ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

London stocks ended higher on Friday, supported by a positive shift in investor sentiment following US consumer confidence ...

GSK plc GSK announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk profile of the Blenrep (belantamab mafodotin-blmf) combination therapy at the ...

Dr Reddy's Laboratories Ltd.'s formulations manufacturing facility was given "Form 483" with seven observations from the ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.